Combination of Vimentin, E-Cadherin, CD44 and CD24 Expression as Predictor Model of Anthracycline Base Neoadjuvant Chemotherapy Response to Stage IIIB Luminal Breast Cancer

Breast cancer is the most common cancer in women in developing countries. This study is an experimental research with pre-experimental typeaimed at analyzing the potential expression of Vimentin, E-Cadherin, CD44 and CD24 as a biomolecular predictor of neoadjuvant chemotherapy response in stage IIIBluminal breast cancer at Dr. Saiful Anwar General Hospital Malang, Indonesia. A total of 35 patients were given neoadjuvant chemotherapy. Expression of Vimentin, E-Cadherin, CD44 and CD24 was examined and analyzed immunohistochemically. Data obtained by immunohistochemical examination and analysis were processed statistically using variance analysis (ANOVA) generated by the SPSS program for Windows. The results showed that neoadjuvant chemotherapy treatment can decrease Vimentin and CD24 expression and increase E-cadherin and CD44 expression. This study concluded that the combination of Vimentin, E-cadherin, CD24 and CD44 expression may be further used as a predictor of anthracycline-basedneoadjuvant chemotherapy response in patients with stage IIIB malignant breast cancer.